Inflammatory exacerbation of hepatic alveolar echinococcosis during dupilumab therapy: A case report
Related Experiment Video
Updated: Mar 19, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
Takumu Hasebe1, Honami Tanaka1, Masami Abe1
1Department of Gastroenterology, Japanese Red Cross Asahikawa Hospital, Asahikawa, Japan.
Background:
Alveolar echinococcosis is a rare but potentially fatal parasitic disease characterized by slow, infiltrative hepatic growth. Disease progression is strongly influenced by host immune status, and atypical courses have been reported in immunocompromised individuals. Dupilumab, a monoclonal antibody targeting interleukin-4 and interleukin-13 signaling, is increasingly used for atopic diseases; however, its impact on latent helminth infections remains unclear. We report a case of hepatic alveolar echinococcosis with pleural involvement occurring during dupilumab therapy, suggesting a possible interaction between targeted immune modulation and disease behavior.
Case Presentation:
A 29-year-old man presented with acute epigastric and left flank pain, fever, and inflammatory markers. Computed tomography revealed a calcified hepatic lesion protruding from the left lateral segment, accompanied by newly developed subdiaphragmatic and left pleural fluid collections suggestive of abscess formation. The patient had been receiving dupilumab for atopic dermatitis. Serological testing confirmed alveolar echinococcosis. Despite broad-spectrum antibiotic therapy, inflammation persisted, and surgical resection was performed, including partial hepatectomy with resection of the diaphragm and pleura. Histopathological examination demonstrated laminated parasitic structures consistent with echinococcal infection in hepatic and pleural tissues, without pulmonary parenchymal involvement. Postoperatively, the patient recovered well and was started on long-term antiparasitic therapy.
Conclusions:
This case highlights an inflammatory exacerbation of hepatic alveolar echinococcosis with pleural extension during dupilumab therapy. Although causality cannot be established, inhibition of type 2 immune pathways may be associated with atypical inflammatory manifestations of latent helminth infections. Clinicians should remain vigilant for inflammatory presentations when prescribing biologic agents, particularly in endemic regions.
Related Concept Videos
Hepatic Drug Excretion: Enterohepatic Cycling
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Pleural Effusion II: Symptoms and Management
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:

